TABLE 1 .
Selleck library screening hits
| Drug class | Drug | Avg fold change in AK signala |
|---|---|---|
| Aminocyclitol | Spectinomycin hydrochloride | 6.6 (± 3.5) |
| Aminoglycoside | Streptomycin sulfate | 44.0 (± 0.7) |
| Tobramycin | 50.0 (± 10.4) | |
| β-Lactam | Doripenem hydrate | 56.0 (± 1.4) |
| Aztreonam | 12.0 (± 9.9) | |
| Fluoroquinolone | Ciprofloxacin | 29.0 (± 0.7) |
| Clinafloxacin | 36.0 (± 24) | |
| Balofloxacin | 32.0 (± 0.2) | |
| Besifloxacin HCl | 34.0 (± 12) | |
| Danofloxacin mesylate | 46.0 (± 15) | |
| Enrofloxacin | 41.0 (± 17) | |
| Levofloxacin | 38.0 (± 2.8) | |
| Lomefloxacin hydrochloride | 59.0 (± 23) | |
| Moxifloxacin hydrochloride | 43.0 (± 5.7) | |
| Nadifloxacin | 35.0 (± 20) | |
| Norfloxacin | 56.0 (± 6.3) | |
| Ofloxacin | 39.0 (± 9.8) | |
| Sitafloxacin hydrate | 41.0 (± 0.6) | |
| Sparfloxacin | 40.0 (± 0.7) | |
| Quinolone | Pefloxacin mesylate | 41.0 (± 1.3) |
| Sarafloxacin HCl | 27.0 (± 6.9) | |
| Glycylcycline | Tigecycline | 38.0 (± 23) |
| Macrolide | Azithromycin | 50.0 (± 1.9) |
| Clarithromycin | 59.0 (± 30) | |
| Erythromycin | 63.0 (± 5.1) | |
| Tetracycline | Oxytetracycline | 6.6 (± 2.1) |
| Methacycline hydrochloride | 62.0 (± 20) | |
| Tetracycline HCl | 56.0 (± 14) | |
| Antitubercular | Rifabutin | 33.0 (± 5.4) |
| Rifampin | 16.0 (± 9.8) | |
| Rifapentine | 4.5 (± 1.6) | |
| Rifaximin | 20.0 (± 20) | |
| Nonantibiotic | Bleomycin sulfate (anticancer) | 3.1 (± 0.5) |
| Zinc pyrithione (antifungal) | 24.0 (± 11) |
a
Data represent average fold increases in adenylate kinase (AK) release in comparison to mock treatment results (standard deviations are indicated in parentheses).